Related Experiment Videos
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Tyrel T Smith1, Sirkka B Stephan1, Howell F Moffett1
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Abstract:
An emerging approach for treating cancer involves programming patient-derived T cells with genes encoding disease-specific chimeric antigen receptors (CARs), so that they can combat tumour cells once they are reinfused. Although trials of this therapy have produced impressive results, the in vitro methods they require to generate large numbers of tumour-specific T cells are too elaborate for widespread application to treat cancer patients. Here, we describe a method to quickly program circulating T cells with tumour-recognizing capabilities, thus avoiding these complications. Specifically, we demonstrate that DNA-carrying nanoparticles can efficiently introduce leukaemia-targeting CAR genes into T-cell nuclei, thereby bringing about long-term disease remission. These polymer nanoparticles are easy to manufacture in a stable form, which simplifies storage and reduces cost. Our technology may therefore provide a practical, broadly applicable treatment that can generate anti-tumour immunity 'on demand' for oncologists in a variety of settings.
Insights
Researchers developed a novel nanoparticle method to engineer T cells for cancer treatment. This approach enables rapid, on-demand generation of tumor-specific T cells, potentially making CAR T-cell therapy more accessible.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer treatment but requires complex in vitro T-cell expansion.
- Current methods for generating CAR T-cells are elaborate and not widely applicable for broad clinical use.
Purpose of the Study:
- To develop a simplified and rapid method for programming T cells with CAR genes for cancer immunotherapy.
- To assess the efficacy of DNA-carrying nanoparticles in delivering CAR genes to T cells for anti-tumor immunity.
Main Methods:
- Utilized polymer nanoparticles to deliver DNA encoding leukemia-targeting CAR genes into circulating T cells.
- Demonstrated efficient gene transfer into T-cell nuclei using nanoparticle technology.
Main Results:
- Achieved efficient genetic modification of T cells using DNA-carrying nanoparticles.
- Observed long-term disease remission in preclinical models, indicating effective anti-tumor immunity.
Conclusions:
- Nanoparticle-mediated CAR gene delivery offers a practical and potentially cost-effective approach for T-cell programming.
- This technology could enable on-demand generation of anti-tumor T cells, expanding the accessibility of CAR T-cell therapy.